PROCEPT BioRobotics (PRCT) to Release Earnings on Tuesday

PROCEPT BioRobotics (NASDAQ:PRCT) will likely be releasing its Q4 2025 results after the market closes on Tuesday, February 24th. Analysts expect PROCEPT BioRobotics to post earnings of ($0.32) per share and revenue of $93.7040 million for the quarter. Interested persons are encouraged to explore the company’s upcoming Q4 2025 earning overview page for the latest details on the call scheduled for Tuesday, February 24, 2026 at 4:30 PM ET.

PROCEPT BioRobotics Trading Up 1.9%

Shares of PROCEPT BioRobotics stock opened at $27.27 on Monday. The company has a market capitalization of $1.52 billion, a P/E ratio of -17.82 and a beta of 0.99. The stock has a fifty day simple moving average of $30.83 and a 200 day simple moving average of $33.92. PROCEPT BioRobotics has a 12-month low of $26.23 and a 12-month high of $70.80. The company has a current ratio of 8.44, a quick ratio of 7.20 and a debt-to-equity ratio of 0.14.

Institutional Investors Weigh In On PROCEPT BioRobotics

Several large investors have recently modified their holdings of the stock. AQR Capital Management LLC raised its holdings in shares of PROCEPT BioRobotics by 7.3% in the 1st quarter. AQR Capital Management LLC now owns 18,892 shares of the company’s stock worth $1,101,000 after purchasing an additional 1,286 shares during the period. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC increased its position in PROCEPT BioRobotics by 9.9% in the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 153,158 shares of the company’s stock worth $8,923,000 after buying an additional 13,767 shares during the last quarter. Intech Investment Management LLC raised its stake in shares of PROCEPT BioRobotics by 54.4% in the first quarter. Intech Investment Management LLC now owns 28,389 shares of the company’s stock valued at $1,654,000 after buying an additional 10,002 shares during the period. Prudential Financial Inc. lifted its position in shares of PROCEPT BioRobotics by 100.4% during the 2nd quarter. Prudential Financial Inc. now owns 6,815 shares of the company’s stock valued at $393,000 after buying an additional 3,415 shares during the last quarter. Finally, State Street Corp grew its stake in shares of PROCEPT BioRobotics by 6.9% during the 2nd quarter. State Street Corp now owns 1,269,110 shares of the company’s stock worth $73,101,000 after acquiring an additional 81,849 shares during the period. Hedge funds and other institutional investors own 89.46% of the company’s stock.

Wall Street Analyst Weigh In

PRCT has been the topic of a number of analyst reports. Jefferies Financial Group upgraded shares of PROCEPT BioRobotics from a “hold” rating to a “strong-buy” rating in a research note on Friday, December 12th. Truist Financial cut their price target on shares of PROCEPT BioRobotics from $50.00 to $47.00 and set a “buy” rating on the stock in a report on Thursday, December 18th. Wells Fargo & Company reduced their price objective on shares of PROCEPT BioRobotics from $58.00 to $51.00 and set an “overweight” rating for the company in a research report on Wednesday, November 5th. Weiss Ratings reiterated a “sell (e+)” rating on shares of PROCEPT BioRobotics in a research note on Thursday, January 22nd. Finally, Leerink Partners restated an “outperform” rating and issued a $55.00 target price on shares of PROCEPT BioRobotics in a research note on Wednesday, November 5th. One analyst has rated the stock with a Strong Buy rating, nine have given a Buy rating, two have assigned a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat.com, PROCEPT BioRobotics presently has an average rating of “Moderate Buy” and an average target price of $53.40.

PROCEPT BioRobotics Company Profile

PROCEPT BioRobotics, Inc is a medical device company specializing in the development and commercialization of robotic systems for the treatment of benign prostatic hyperplasia (BPH). The company’s technology leverages precision robotics and real-time imaging to perform minimally invasive procedures, aiming to reduce patient recovery time and improve clinical outcomes compared to traditional surgical approaches.

The company’s flagship product, the AquaBeam Robotic System, uses a high-velocity waterjet to selectively remove prostate tissue while preserving surrounding healthy structures.